A reference work, not a recommendation to use: this profile describes mechanism and evidence and does not replace medical advice. The claims come from marketing and forums and are tested here, not endorsed.

Claims checked

  • Substantial weight loss (“weight-loss shot”)

    Proven benefit

    Energy & metabolism · Patients: overweight with a comorbidity or obesity, without diabetes · Human, randomised manufacturer-fundedAccording to their funding or competing-interest statements, all studies behind this result were paid for, wholly or in part, by the maker of the product or compound, or list employees of the maker among their authors. Manufacturer-funded studies on average come out more favourably for the product.

    In STEP 1 (1961 participants, 68 weeks) −14.9% versus −2.4% with placebo [7]. One year after discontinuation, two thirds of the loss had returned [8]. Both studies funded by the manufacturer Novo Nordisk or with authors employed there [7][8]; for people of normal weight who only want to change their figure, there is no efficacy study.

  • Protects heart and vessels

    Only proven in patients

    Heart & blood vessels · Patients: cardiovascular disease and overweight, without diabetes · Human, randomised manufacturer-fundedAccording to their funding or competing-interest statements, all studies behind this result were paid for, wholly or in part, by the maker of the product or compound, or list employees of the maker among their authors. Manufacturer-funded studies on average come out more favourably for the product.

    SELECT: 6.5% versus 8.0% major cardiovascular events (hazard ratio 0.80) in 17,604 people over about 40 months; treatment discontinuations because of side effects twice as frequent [10]. Funded by Novo Nordisk [10].

  • Less craving for alcohol

    Single unconfirmed finding

    Mood & stress · Patients: alcohol use disorder, not treatment-seeking · Human, randomised small studiesEvery study behind this level and result had fewer than 100 participants. Small studies report larger effects on average than large ones, so the result is less certain.

    A phase 2 RCT with 48 participants over 9 weeks: less alcohol in the laboratory test, less craving and fewer drinks per drinking day, but not fewer drinking days [11].

  • Protects the brain from Alzheimer disease

    No benefit

    Cognition & focus · Patients: early symptomatic Alzheimer disease · Human, randomised manufacturer-fundedAccording to their funding or competing-interest statements, all studies behind this result were paid for, wholly or in part, by the maker of the product or compound, or list employees of the maker among their authors. Manufacturer-funded studies on average come out more favourably for the product.

    Two phase 3 RCTs with 3808 participants: no slowing on the CDR-SB after 104 weeks (difference −0.08 and 0.10) [12]. Whether semaglutide prevents Alzheimer disease in healthy people has not been studied. Funded by Novo Nordisk [12].

small studies: Every study behind this level and result had fewer than 100 participants. Small studies report larger effects on average than large ones, so the result is less certain.

manufacturer-funded: According to their funding or competing-interest statements, all studies behind this result were paid for, wholly or in part, by the maker of the product or compound, or list employees of the maker among their authors. Manufacturer-funded studies on average come out more favourably for the product.

Mechanism of action

Evidence map: Semaglutide

Each line stands for a published finding; line style and color show where it comes from. The filter hides weaker evidence levels. Sources: see references.

Semaglutide is an analog of the human gut hormone GLP-1 with two amino acid substitutions (Aib at position 8, Arg at position 34) and a fatty acid attached to lysine 26 via a linker; this fatty acid binds the molecule to serum albumin and, together with Aib8, protects it from rapid degradation [1]. Its affinity for the GLP-1 receptor is 0.38 nM, about three times lower than that of its predecessor liraglutide; the plasma half-life was 46.1 hours in minipigs after intravenous administration [1] and about one week in humans [2]. As a tablet, semaglutide is absorbed only together with the excipient SNAC, transcellularly in the gastric mucosa directly next to the tablet [3]; oral bioavailability under study conditions is 0.8% and varies greatly within the same person [2].

In rodents, semaglutide does not cross the blood-brain barrier but reaches the brainstem, septum and hypothalamus via the circumventricular organs; it activated ten brain regions, including areas of meal termination, and lowered weight without a decrease in energy expenditure [4]. In humans, a placebo-controlled study in 72 adults with obesity confirmed the appetite mechanism: energy intake at an ad libitum meal was 35% lower after 20 weeks, hunger and food cravings decreased, and delayed gastric emptying could not be demonstrated at this time point [5]. Via the GLP-1 receptor of the pancreas, semaglutide lowers blood glucose in type 2 diabetes: the long-term marker HbA1c fell by 1.4 to 1.5 percentage points versus placebo in the pivotal study SUSTAIN 1 [6].

In the study STEP 1 with 1961 adults with overweight or obesity without diabetes, participants on semaglutide lost 14.9% of their body weight in 68 weeks, versus 2.4% with placebo [7]. One year after discontinuation, they had regained two thirds of the weight lost, and most metabolic improvements had reversed [8]. A systematic review of randomized studies on incretin drugs found that on average 28% of the weight loss was accounted for by muscle-related measures [9]. In SELECT, with 17,604 people with cardiovascular disease and overweight but without diabetes, semaglutide reduced major cardiovascular events by 20% (hazard ratio 0.80) [10]; by what mechanism is open. STEP 1 including follow-up, SUSTAIN 1 and SELECT were funded by the manufacturer Novo Nordisk.

GLP-1 receptors are also found in reward pathways [4]. In a small randomized study with 48 people with alcohol use disorder, semaglutide at a low dose level reduced the amount of alcohol drunk in the laboratory and craving, but not the number of drinking days [11]. In contrast, semaglutide as a tablet did not slow progression in two phase 3 studies with 3808 people with early Alzheimer disease [12]. On risks, meta-analyses of randomized studies show an increased risk of gallbladder and biliary tract disease [13]; in mice, GLP-1 agonists trigger thyroid C-cell proliferation via the receptor [14]. One observational study found more cases of ischemic optic nerve damage (NAION) under semaglutide [15], whereas a large registry study found no increased risk of suicidal ideation [16]. Products from illegal online pharmacies were contaminated and mislabeled in a test-purchase study [17].

Targets

TargetTypeActionKey dataEvidence
GLP-1 receptorReceptorAgonistAffinity 0.38 nM (laboratory), about three times lower than liraglutide Laboratory[1]
GLP-1 receptors in circumventricular organs, brainstem and hypothalamusReceptorAgonistc-Fos activation in 10 brain regions (rodent) Animal study[4]
Serum albuminOtherBindingFatty acid chain at lysine 26; half-life ≈ 1 week (human) Laboratory[1][2]
GLP-1 receptor on thyroid C cells (class effect)ReceptorAgonistCalcitonin ↑ and C-cell hyperplasia only in mice with the receptor Animal study[14]

Effect profile

Which signaling systems the compound affects according to current data. ↑ enhanced, ↓ dampened, ≈ modulated, ○ no effect; dots = evidence level.

  • Dopamineunclear · Tyrosine hydroxylase in the area postrema increased, reward pathways involved (rat); dopamine itself not measured[4]
  • Noradrenalineno data
  • Serotoninno data
  • Acetylcholineno data
  • Glutamate · AMPAno data
  • Glutamate · NMDAno data
  • GABAno data
  • Histamineno data
  • Orexinno data
  • Adenosineno data
  • Opioidsno data
  • Melatoninno data
  • Neurotrophinsno data
  • Blood flowno data
  • Nitric oxideno data
  • Energy metabolism↓ · Energy intake at an ad libitum meal lowered by 35% (RCT); energy expenditure not lowered in rodents[4][5]
  • Insulin · glucosemodulated · Lowers the long-term blood glucose marker HbA1c by 1.4–1.5 percentage points versus placebo in type 2 diabetes (RCT)[6]
  • Inflammation · oxidativeno data
  • Stress axisno data
  • Testosterone axisno data
  • Endocannabinoidsno data
  • Autophagy · senescenceno data
  • Immune systemno data
  • Lipid metabolismno data
  • Coagulation · fibrinolysisno data
  • Methylationno data

Routes of administration and bioavailability

How much of a compound reaches the blood or target tissue depends on the route into the body and on the dosage form. All routes of administration explained

  • Subcutaneous (under the skin) · Prefilled pen (weekly injection)

    Albumin binding prolongs the effect; half-life in humans about one week [2], mean residence time after subcutaneous administration in minipigs 63.6 hours [1]. Absolute bioavailability not verified here.

    Human, non-randomised

  • Oral (swallowed) · Tablet with the absorption enhancer SNAC

    ≈ 0.8% (human, population pharmacokinetic model)

    Absorption in the stomach, transcellular and only near the tablet surface; no absorption without SNAC [3]. Fasting time and water volume change absorption; the variability within the same person was 137% [2]. Both papers come from the manufacturer.

    Human, non-randomised

  • Subcutaneous (under the skin) · Powder vials from illegal online pharmacies

    In three test purchases, purity was only 7.7–14.4% instead of the stated 99%, endotoxins in all samples, active ingredient content 29–39% above the stated amount; prefilled pens that were ordered never arrived [17].

    Laboratory

Human studies

  • STEP 1: weight reduction

    RCT, double-blind, placebo-controlled · Patients: overweight with a comorbidity or obesity, without diabetes · n = 1961 · 68 weeks

    Measured: Weight change in %

    Result: −14.9% versus −2.4%; discontinuation because of gastrointestinal complaints 4.5% versus 0.8%.[7]

    Human, randomised

  • STEP 1: one year after discontinuation

    follow-up of an RCT (exploratory) · Patients: overweight or obesity, without diabetes · n = 327 · 52 weeks without treatment

    Measured: Weight, cardiometabolic values

    Result: Two thirds of the loss regained; net −5.6% after 120 weeks; metabolic values almost back to baseline.[8]

    Human, randomised

  • SELECT: cardiovascular events

    RCT, double-blind, placebo-controlled, event-driven · Patients: cardiovascular disease and overweight, without diabetes · n = 17604 · mean 39.8 months

    Measured: cardiovascular death, myocardial infarction, stroke

    Result: Hazard ratio 0.80 (95% CI 0.72–0.90); discontinuations because of side effects 16.6% versus 8.2%.[10]

    Human, randomised

  • SUSTAIN 1: type 2 diabetes

    RCT, double-blind, placebo-controlled · Patients: type 2 diabetes without prior treatment · n = 388 · 30 weeks

    Measured: HbA1c, body weight

    Result: HbA1c −1.43 and −1.53 percentage points versus placebo; nausea in 20–24% versus 8%.[6]

    Human, randomised

  • Appetite and energy intake

    RCT, double-blind, placebo-controlled · Patients: obesity · n = 72 · 20 weeks

    Measured: Gastric emptying, energy intake, appetite

    Result: Energy intake −35%; less hunger and food cravings; no demonstrably delayed gastric emptying.[5]

    Human, randomised

  • Alcohol use disorder

    RCT, double-blind, phase 2 · Patients: alcohol use disorder · n = 48 · 9 weeks

    Measured: Alcohol consumption in the laboratory, craving, drinking behavior

    Result: Less alcohol in the laboratory test and less craving; drinking days unchanged.[11]

    Human, randomised

  • evoke and evoke+: early Alzheimer disease

    two RCTs, double-blind, placebo-controlled, phase 3 · Patients: early symptomatic Alzheimer disease · n = 3808 · 104 weeks (primary endpoint)

    Measured: CDR-SB

    Result: No difference from placebo; studies terminated because of lack of efficacy.[12]

    Human, randomised

  • NAION risk

    retrospective, matched cohort (one clinic) · Patients: type 2 diabetes or overweight, presented to neuro-ophthalmology · n = 1689 · up to 36 months

    Measured: non-arteritic anterior ischemic optic neuropathy

    Result: Hazard ratio 4.28 (diabetes) and 7.64 (overweight); causality open.[15]

    Human, non-randomised

Risks and warnings

  • Gastrointestinal complaints

    Nausea and diarrhea are the most common side effects, mostly transient; 4.5% discontinued for this reason in STEP 1 (placebo 0.8%) [7]. In SELECT, side effects led to discontinuation in 16.6% (placebo 8.2%) [10].

    Human, randomised

  • Gallbladder and biliary tract disease

    Meta-analysis of 76 RCTs of GLP-1 agonists: relative risk 1.37, in weight-reduction studies 2.29; higher at high dose levels and with longer use [13].

    Human, randomised

  • Weight regain after discontinuation

    One year after discontinuation, two thirds of the weight loss returned, metabolic improvements largely lost [8].

    Human, randomised

  • Loss of fat-free mass

    In randomized studies of incretin drugs, on average 28% of the weight loss was accounted for by muscle-related measures; consequences for bodily function were not measured in any study [9].

    Human, randomised

  • Ischemic optic nerve damage (NAION)

    In an observational study from one clinic, markedly more frequent under semaglutide (hazard ratio 4.28 and 7.64); causality not demonstrated [15].

    Human, non-randomised

  • Thyroid C cells (animal finding)

    In mice, GLP-1 agonists trigger a calcitonin rise and C-cell hyperplasia via the GLP-1 receptor; studied with liraglutide and exenatide, not with semaglutide; relevance for humans unclear [14].

    Animal study

  • Counterfeit and contaminated products

    42% of the online pharmacies found were illegal; tested vials had 7.7–14.4% purity and contained endotoxins [17].

    Laboratory

Interactions

  • Other oral medicines (gastric emptying): After 20 weeks, gastric emptying, measured via paracetamol absorption, was not demonstrably delayed [5]; data from the initial phase of treatment were not checked here.

Fact check: common claims

  • refuted

    “With semaglutide you lose only fat, no muscle”

    On average, 28% of the weight loss in randomized studies was accounted for by muscle-related measures [9].

  • refuted

    “The weight lost stays off after discontinuation”

    One year after discontinuation, two thirds of the loss had returned [8].

  • not supported

    “Ozempic triggers suicidal thoughts”

    In a registry study of over 240,000 people with overweight, the risk was lower than with other weight-loss drugs (hazard ratio 0.27); observational data, not an RCT [16].

  • refuted

    “Semaglutide slows Alzheimer disease”

    Two phase 3 RCTs with 3808 participants showed no slowing [12].

  • refuted

    “Semaglutide from the internet is the same as from the pharmacy”

    Test purchases without a prescription delivered contaminated, mislabeled vials or nothing at all [17].

Pharmacokinetics

Absorption
Subcutaneous as a weekly injection; orally only with SNAC, bioavailability ≈ 0.8% with marked variability [2][3].
Half-life
About one week (human) [2]; 46.1 hours after intravenous administration in minipigs [1].
Metabolism
Stabilized against rapid enzymatic degradation by albumin binding and Aib at position 8 [1].
Entry into the brain
Does not cross the blood-brain barrier in rodents; reaches brainstem, septum and hypothalamus via circumventricular organs [4].

Legal status

Germany
Also authorized as a medicine in Germany through the central EU authorization [18]; prescription requirement and reimbursement not checked in registers.
EU
Approved by the EMA for weight reduction [18], and also in type 2 diabetes as an injection and as a tablet [2]. Since March 26, 2026, additionally conditionally authorized (as Kayshild), together with diet and exercise, for MASH without cirrhosis with moderate to advanced fibrosis (F2–F3) [20].
USA
Approved by the FDA for weight reduction [18] and in type 2 diabetes as an injection and as a tablet [2]. Since August 2025, also under accelerated approval (based on a surrogate endpoint) as Wegovy for MASH with moderate to advanced fibrosis [19].

Related compounds

Tirzepatidesame classRetatrutidesame class

Open questions

  • By what mechanism does semaglutide lower cardiovascular events, and how much of it is due to the weight loss?
  • Is the increase in ischemic optic nerve damage detectable in randomized data?
  • What are the consequences of the loss of fat-free mass for strength and function, especially in older age?
  • Is the effect on alcohol craving confirmed in larger studies?

References

  1. Lau J, Bloch P, Schäffer L, Pettersson I, Spetzler J, Kofoed J, et al. Discovery of the once-weekly glucagon-like peptide-1 (GLP-1) analogue semaglutide. J Med Chem. 2015;58(18):7370–80. doi:10.1021/acs.jmedchem.5b00726 · PubMed
  2. Overgaard RV, Navarria A, Ingwersen SH, Bækdal TA, Kildemoes RJ. Clinical pharmacokinetics of oral semaglutide: analyses of data from clinical pharmacology trials. Clin Pharmacokinet. 2021;60(10):1335–48. doi:10.1007/s40262-021-01025-x · PubMed
  3. Buckley ST, Bækdal TA, Vegge A, Maarbjerg SJ, Pyke C, Ahnfelt-Rønne J, et al. Transcellular stomach absorption of a derivatized glucagon-like peptide-1 receptor agonist. Sci Transl Med. 2018;10(467):eaar7047. doi:10.1126/scitranslmed.aar7047 · PubMed
  4. Gabery S, Salinas CG, Paulsen SJ, Ahnfelt-Rønne J, Alanentalo T, Baquero AF, et al. Semaglutide lowers body weight in rodents via distributed neural pathways. JCI Insight. 2020;5(6):e133429. doi:10.1172/jci.insight.133429 · PubMed
  5. Friedrichsen M, Breitschaft A, Tadayon S, Wizert A, Skovgaard D. The effect of semaglutide 2.4 mg once weekly on energy intake, appetite, control of eating, and gastric emptying in adults with obesity. Diabetes Obes Metab. 2021;23(3):754–62. doi:10.1111/dom.14280 · PubMed
  6. Sorli C, Harashima SI, Tsoukas GM, Unger J, Karsbøl JD, Hansen T, et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1): a double-blind, randomised, placebo-controlled, parallel-group, multinational, multicentre phase 3a trial. Lancet Diabetes Endocrinol. 2017;5(4):251–60. doi:10.1016/S2213-8587(17)30013-X · PubMed
  7. Wilding JPH, Batterham RL, Calanna S, Davies M, Van Gaal LF, Lingvay I, et al. Once-weekly semaglutide in adults with overweight or obesity. N Engl J Med. 2021;384(11):989–1002. doi:10.1056/NEJMoa2032183 · PubMed
  8. Wilding JPH, Batterham RL, Davies M, Van Gaal LF, Kandler K, Konakli K, et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide: the STEP 1 trial extension. Diabetes Obes Metab. 2022;24(8):1553–64. doi:10.1111/dom.14725 · PubMed
  9. Batsis JA, Gavras A, Gross DC, Cheever CR, Da Silva BR, Meira Filho LF, et al. Effect of incretin-based and nonpharmacologic weight loss on body composition: a systematic review. Ann Intern Med. 2026;179(7):996–1013. doi:10.7326/ANNALS-25-00478 · PubMed
  10. Lincoff AM, Brown-Frandsen K, Colhoun HM, Deanfield J, Emerson SS, Esbjerg S, et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023;389(24):2221–32. doi:10.1056/NEJMoa2307563 · PubMed
  11. Hendershot CS, Bremmer MP, Paladino MB, Kostantinis G, Gilmore TA, Sullivan NR, et al. Once-weekly semaglutide in adults with alcohol use disorder: a randomized clinical trial. JAMA Psychiatry. 2025;82(4):395–405. doi:10.1001/jamapsychiatry.2024.4789 · PubMed
  12. Cummings JL, Atri A, Sano M, Zetterberg H, Scheltens P, Knop FK, et al. Efficacy and safety of oral semaglutide 14 mg (flexible dose) in early-stage symptomatic Alzheimer's disease (evoke and evoke+): two phase 3, randomised, placebo-controlled trials. Lancet. 2026;407(10544):2167–79. doi:10.1016/S0140-6736(26)00459-9 · PubMed
  13. He L, Wang J, Ping F, Yang N, Huang J, Li Y, et al. Association of glucagon-like peptide-1 receptor agonist use with risk of gallbladder and biliary diseases: a systematic review and meta-analysis of randomized clinical trials. JAMA Intern Med. 2022;182(5):513–9. doi:10.1001/jamainternmed.2022.0338 · PubMed
  14. Madsen LW, Knauf JA, Gotfredsen C, Pilling A, Sjögren I, Andersen S, et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology. 2012;153(3):1538–47. doi:10.1210/en.2011-1864 · PubMed
  15. Hathaway JT, Shah MP, Hathaway DB, Zekavat SM, Krasniqi D, Gittinger JW, et al. Risk of nonarteritic anterior ischemic optic neuropathy in patients prescribed semaglutide. JAMA Ophthalmol. 2024;142(8):732–9. doi:10.1001/jamaophthalmol.2024.2296 · PubMed
  16. Wang W, Volkow ND, Berger NA, Davis PB, Kaelber DC, Xu R. Association of semaglutide with risk of suicidal ideation in a real-world cohort. Nat Med. 2024;30(1):168–76. doi:10.1038/s41591-023-02672-2 · PubMed
  17. Ashraf AR, Mackey TK, Vida RG, Kulcsár G, Schmidt J, Balázs O, et al. Multifactor quality and safety analysis of semaglutide products sold by online sellers without a prescription: market surveillance, content analysis, and product purchase evaluation study. J Med Internet Res. 2024;26:e65440. doi:10.2196/65440 · PubMed
  18. Sidrak WR, Kalra S, Kalhan A. Approved and emerging hormone-based anti-obesity medications: a review article. Indian J Endocrinol Metab. 2024;28(5):445–60. doi:10.4103/ijem.ijem_442_23 · PubMed
  19. U.S. Food and Drug Administration. FDA approves treatment for serious liver disease known as „MASH“ [Internet]. Silver Spring (MD): FDA; 15.08.2025 [abgerufen 24.10.2026]. Verfügbar unter: https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-treatment-serious-liver-disease-known-mash
  20. European Medicines Agency. Kayshild (semaglutide): EPAR [Internet]. Amsterdam: EMA; 2026 [abgerufen 24.10.2026]. Verfügbar unter: https://www.ema.europa.eu/en/medicines/human/EPAR/kayshild
How this profile was checked

Last reviewed: 2026-10-24. All sources with a DOI or PMID were resolved automatically via Crossref or doi.org and PubMed.

Translated from the German profile (version of 2026-10-24); translation checked on 2026-10-26.

Checked

  • Local check on October 24, 2026: MASH approvals taken over with the sources from the article “Semaglutid bei MASH” (semaglutide in MASH) and re-read on the regulatory agency pages: FDA, accelerated approval for Wegovy in MASH with moderate to advanced fibrosis (page dated August 15, 2025) [19]; EMA, Kayshild, conditional authorization on March 26, 2026 in non-cirrhotic MASH with fibrosis F2–F3, together with diet and exercise [20]. Abstracts [7][8][10][11][12][13][15][16][17] re-read.
  • All abstracts read via PubMed (XML), DOIs and PMIDs reconciled with tools/pruefe_profile.py.
  • Key figures checked against abstracts: Aib8/Arg34, Lys26, 0.38 nM, 46.1 h, MRT 63.6 h [1]; F 0.8%, variability 137% [2]; absorption in the stomach, transcellular, SNAC required [3]; blood-brain barrier, 10 areas, energy expenditure not lowered [4]; n = 72, −35%, gastric emptying [5]; n = 388, HbA1c difference −1.43/−1.53 [6]; n = 1961, −14.9 vs. −2.4%, discontinuation 4.5 vs. 0.8% [7]; n = 327, two thirds, net −5.6% [8]; 35 studies, median 28.3% [9]; n = 17,604, HR 0.80, discontinuation 16.6 vs. 8.2% [10]; n = 48, laboratory drinking, drinking days unchanged [11]; n = 3808, difference −0.08/0.10 [12]; 76 RCTs, RR 1.37/2.29 [13]; mouse, GLP-1R knockout [14]; HR 4.28/7.64 [15]; n = 240,618, HR 0.27 [16]; purity 7.7–14.4%, endotoxin, 42.3% illegal [17].
  • In the full text (PMC8505367): half-life ≈ 1 week, approval in type 2 diabetes as an injection and as a tablet [2]; (PMC11642516): approval for weight reduction by the FDA and EMA [18].
  • Funding according to abstract/conflict-of-interest statement: Novo Nordisk for [2][5][6][7][8][10][12] (full text [8]: “The STEP 1 trial was funded by Novo Nordisk”); authors employed by the manufacturer for [1][2][3][4][5]; [9] without funding; [16] no conflicts of interest.
  • ClinicalTrials.gov: 818 entries for “semaglutide” (October 23, 2026); no entry from the sponsor “Hudson Biotech” found.
  • October 26, 2026, precision flags (m004; rules in the guideline under “Number rule and precision flags”, implementation by Claude pending confirmation by Tilman): “Substantial weight loss (‘weight-loss shot’)”: manufacturer-funded – [7] “Funded by Novo Nordisk” according to the abstract; [8] several authors employed by Novo Nordisk according to the conflict-of-interest statement. “Protects heart and vessels”: manufacturer-funded – [10] “Funded by Novo Nordisk” according to the abstract. “Less craving for alcohol”: “kleine_studien” – [11] 48 participants (abstract). “Protects the brain from Alzheimer disease”: manufacturer-funded – [12] several authors employed by Novo Nordisk according to the conflict-of-interest statement. Cross-check October 26, 2026: evidence for the flags (participant numbers, direction, funding) incorporated into the begruendung and rechecked against abstracts or full texts.

Not verified

  • Absolute bioavailability after subcutaneous administration (no primary source with an abstract found).
  • German status (prescription requirement, reimbursement) not checked in registers; EMA pages blocked in the cloud session.
  • Doping status not checked (no peer-reviewed source searched for).
  • Data from the JAMA research letter on pancreatitis and bowel obstruction (Sodhi 2023) not included because neither abstract nor full text was freely readable.
  • Later analyses of NAION risk (e.g., regulatory assessments, further cohorts) not checked.

No dosages, no sources of supply. This information does not replace medical advice.

Spotted an error or missing something?

Request a compound, suggest an improvement or report an error. Every message is read.

Type of message

The website stores nothing. The button opens your email app with a pre-filled message.